CAR T-cell Therapy

Brexu-cel led to an ORR of 91% in patients with relapsed/refractory MCL who were naive to BTK inhibitors, according to new data from the ZUMA-2 trial.

Cilta-cel boosted MRD-negativity rates in lenalidomide-refractory multiple myeloma, according to updated results from CARTITUDE-4.

Tisagenlecleucel maintained long-term efficacy and safety in relapsed/refractory follicular lymphoma.

Brexucabtagene autoleucel demonstrated similar efficacy across age groups of patients with relapsed/refractory B-cell acute lymphoblastic leukemia

Treatment with bicistronic CD19/CD22 CAR T-cell therapy led to high 1-year EFS and OS rates among children with relapsed/refractory B-ALL.

Jennifer Amengual, MD, discusses real-world outcomes with CAR T-cell therapy and bispecific antibodies in patients with DLBCL.

Here is your snapshot of all treatment options that the FDA cleared in November 2024 spanning tumor types.

In case you missed any, read a recap of every episode of OncLive On Air that aired in November 2024.

Hematologic oncologists offer their perspective on the current and potential future standing of CAR T-cell therapies in the relapsed/refractory ALL treatment landscape.

Elias Jabbour, MD, highlights the significance of obecabtagene autoleucel’s approval for patients with B-cell precursor ALL and data from the FELIX trial.

Syed Abbas Ali, MBBS, discusses how CAR T-cell therapies and bispecific antibodies have altered treatment in relapsed/refractory multiple myeloma.

David R. Oveisi, MD, discusses how the expanded indications for ide-cel and cilta-cel are affecting treatment decision-making in multiple myeloma.

Early cytokine induction after CAR T-cell therapy infusion predicts CAR expansion in patients with leukemia or lymphoma treated with axi-cel or brexu-cel.

Obe-cel wins FDA approval in relapsed/refractory B-cell ALL, FDA approval is sought for sunvozertinib in EGFR exon 20–positive NSCLC, and more.

The FDA has approved obecabtagene autoleucel for relapsed/ refractory B-cell precursor acute lymphoblastic leukemia.

Michel Delforge, MD, PhD, discusses an indirect comparison of cilta-cel vs standard-of-care regimens in lenalidomide-refractory multiple myeloma.

The FDA has granted regenerative medicine advanced therapy to ALLO-316 in CD70-positive advanced or metastatic renal cell carcinoma.

Daniel DeAngelo MD, PhD, discusses the evolution of management strategies and treatment goals across several hematologic malignancies.

CAR T-cell therapy demonstrated efficacy and manageable safety in mantle cell lymphoma in a systematic review of prospective and real-world studies.

NT-I7 with CAR T-cell therapy demonstrated an 81.1% objective response rate in relapsed DLBCL patients and a manageable safety profile.

Perioperative nivolumab receives FDA approval for resectable NSCLC, acalabrutinib sNDA gets priority review for MCL, and more from OncLive this week.

The GPRC5D-targeted CAR T-cell therapy BMS-986393 led to an objective response rate of 96% in patients with relapsed/refractory multiple myeloma.

Treatment with P-BCMA-ALLO1 demonstrated clinical activity and a manageable safety profile in heavily pretreated, relapsed/refractory multiple myeloma.

All patients with relapsed/refractory multiple myeloma experienced a response when treated with anitocabtagene autoleucel in a phase 1 trial.

Mayo Clinic researchers mined the molecular foundations of cancer and uncovered a new reason CAR-T cell therapy fails in some patients.

The phase 3 KarMMa-9 trial of ide-cel plus lenalidomide maintenance in newly diagnosed multiple myeloma after ASCT has discontinued enrollment.

This list features a snapshot of key August FDA oncology decisions, efforts to integrate health equity into guideline development, and more.

Tisagenlecleucel is moving to earlier lines of therapy for pediatric and young adult patients with relapsed/refractory B-cell acute lymphoblastic leukemia.

Here is your snapshot of all therapeutic options that the FDA approved in August 2024 and their clinical implications.

The FDA has granted fast track designation to the allogeneic CAR T-cell therapy CB-012 for relapsed/refractory acute myeloid leukemia.